Mylan Laboratories Inc. First Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Mylan Laboratories, Inc. (NASDAQ:MYL) will unveil its latest earnings on Thursday, April 26, 2012. Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets, and distributes pharmaceuticals and active pharmaceutical ingredients.

Mylan Laboratories, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average analyst estimate is for profit of 51 cents per share, a rise of 15.9% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from 55 cents. Between one and three months ago, the average estimate moved down. It also has dropped from 52 cents during the last month. For the year, analysts are projecting net income of $2.42 per share, a rise of 23.5% from last year.

Past Earnings Performance: The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked profit of 53 cents per share versus a mean estimate of net income of 50 cents per share.

Investing Insights: What’s the Future of Microsoft’s Stock?

Wall St. Revenue Expectations: Analysts are projecting a rise of 9% in revenue from the year-earlier quarter to $1.58 billion.

Analyst Ratings: Analysts are optimistic about this stock, with 12 analysts rating it as a buy, one rating it as a sell and five rating it as a hold.

A Look Back: In the fourth quarter of the last fiscal year, profit rose more than sixfold to $129.5 million (30 cents a share) from $19.8 million (-3 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 6.7% to $1.53 billion from $1.43 billion.

Key Stats:

On the top line, the company has a chance to extend a streak of four straight quarters of revenue increases. Revenue rose 12.1% in the first quarter of the last fiscal year, 15% in the second quarter and 16.3% in the third quarter before rising again in the fourth quarter.

Stock Price Performance: Between February 23, 2012 and April 20, 2012, the stock price had fallen $1.85 (-7.8%), from $23.69 to $21.84. The stock price saw one of its best stretches over the last year between June 22, 2011 and July 1, 2011, when shares rose for eight straight days, increasing 9.3% (+$2.12) over that span. It saw one of its worst periods between April 27, 2011 and May 6, 2011 when shares fell for eight straight days, dropping 5.3% (-$1.33) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Steve Blank: How to Build a Billion Dollar Startup

Is Apple Beating Google on User Engagement?

Gold and Silver Miners Put Real Money Where Their Mouth Is